Methods of treating glioblastoma

Abstract

Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel.

1 - 30 . (canceled) 
     
     
         31 . A method of treating glioblastoma in a human subject in need thereof, the method comprising:
 administering concurrently to the subject (i) of 4-iodo-3-nitrobenzamide or a salt, metabolite or prodrug thereof, and (ii) temozolomide, and further administering radiation.   
     
     
         32 . The method of  claim 31 , wherein about 5 milligrams per kilogram (mg/kg) to about 10 mg/kg of the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the human subject. 
     
     
         33 . The method of  claim 32 , wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject in an amount of about 8 mg/kg. 
     
     
         34 . The method of  claim 32 , wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject twice a week. 
     
     
         35 . The method of  claim 34 , wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject for about six weeks. 
     
     
         36 . The method of  claim 31 , wherein 75 milligrams per square meter (mg/m 2 ) to about 200 mg/m 2  of the temozolomide is administered to the subject. 
     
     
         37 . The method of  claim 36 , wherein 150 milligrams per square meter (mg/m 2 ) to about 200 mg/m 2  of the temozolomide is administered to the subject. 
     
     
         38 . The method of  claim 36 , wherein temozolomide is administered to the subject daily. 
     
     
         39 . The method of  claim 36 , wherein temozolomide is administered to the subject for about six weeks. 
     
     
         40 . The method of  claim 31 , wherein about 60 grays (Gy) of total radiation is administered to the subject. 
     
     
         41 . The method of  claim 40 , the radiation is administered to the subject over a course of about six weeks. 
     
     
         42 . The method of  claim 31 , further comprising a maintenance regimen comprising administering (i) 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof, and (ii) temozolomide. 
     
     
         43 . The method of  claim 42 , wherein about 5 mg/kg to about 10 mg/kg of 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject during the maintenance regimen. 
     
     
         44 . The method of  claim 43 , wherein about 8.6 mg/kg of the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof is administered to the subject during the maintenance regimen. 
     
     
         45 . The method of  claim 43 , wherein the 4-iodo-3-nitrobenzamide or a salt, metabolite or prodrug thereof is administered to the subject twice a week. 
     
     
         46 . The method of  claim 42 , wherein about 75 mg/m 2  to about 200 mg/m 2  of the temozolomide is administered to the subject during the maintenance regimen. 
     
     
         47 . The method of  claim 42 , wherein the 4-iodo-3-nitrobenzamide or the salt, metabolite or prodrug thereof and the temozolomide is administered to the subject for about 1-6 cycles, wherein a single cycle is about 28 days. 
     
     
         48 . The method of  claim 47 , wherein the temozolomide is administered to the subject on Days 1-5 of each cycle. 
     
     
         49 . The method of  claim 31 , wherein the glioblastoma is a primary glioblastoma or a secondary tumor. 
     
     
         50 . The method of  claim 31 , wherein the subject has a grade III or grade IV glioblastoma.